Scientist, Non-clinical Toxicology jobs in United States
cer-icon
Apply on Employer Site
company-logo

MapLight Therapeutics, Inc. · 6 hours ago

Scientist, Non-clinical Toxicology

MapLight Therapeutics is a clinical stage biotech company that focuses on drug discovery for central nervous system disorders. The role involves designing, executing, and interpreting non-clinical safety studies to support neurology drug discovery and development programs.

BiopharmaBiotechnologyLife ScienceMedical
check
H1B Sponsor Likelynote

Responsibilities

Collaborate with program team leads and subject matter experts (e.g., discovery, bioanalysis, pharmacokinetics, CMC) to design safety pharmacology and toxicology studies, aligning with company objectives and regulatory standards
Serve as the primary sponsor representative for CROs, handling all aspects of study outsourcing, including requesting quotes, negotiating contracts, and managing study timelines
Oversee the design, execution, and data interpretation of nonclinical safety studies conducted at CROs, ensuring robust and high-quality data generation
Review study reports and SEND datasets to ensure quality, timeliness, and readiness for regulatory submissions
Effectively communicate study findings project leads and senior management, addressing and resolving any study-related issues promptly
Contribute to the preparation, review, and/or QC of nonclinical sections in regulatory submission documents (e.g., IBs, INDs, CTAs, NDAs, PIPs, Scientific Advice, annual reports, briefing documents) as needed
Participate in issue-resolution teams, providing scientific guidance to address toxicology-related challenges and drive effective problem-solving

Qualification

Toxicology expertiseGLP regulations knowledgeStudy director experienceDABT CertificationCNS safety considerationsCritical thinkingLeadership skillsInterpersonal skillsCommunication skillsNegotiation skills

Required

PhD with 3+ years, MS with a minimum of 5+ years, or BS with a minimum of 8 years of hands-on experience as a study director in toxicology within the pharmaceutical or biotechnology industry or at CROs (additional experience monitoring studies on-site at CROs is helpful)
Proven track record of successfully directing and/or monitoring toxicology studies across various modalities and in various species (rodent, dog, nhp)
Advanced knowledge of toxicology in support of drug development
In-depth understanding of GLP regulations and regulatory guidance for nonclinical evaluations
Demonstrated enthusiasm for scientific research and a commitment to maintaining high-quality standards in toxicology study operations
Strong critical thinking, analysis, and leadership skills
Self-motivated to meet performance objectives and to prioritize job-related tasks
Ability to adapt to dynamic project needs and manage studies across different time zones
Excellent interpersonal, communication, and negotiation skills, with a collaborative mindset
Willingness to travel on business to CROs as needed

Preferred

Board Certification in toxicology (DABT Certification) or working towards board certification preferred but not required

Benefits

Annual bonus opportunity
Medical
Dental
Vision
Life and AD&D
Short term and long term disability
401(K) plan with match
Stock options
Flexible non-accrual paid time off
Parental leave

Company

MapLight Therapeutics, Inc.

twittertwittertwitter
company-logo
Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).

H1B Sponsorship

MapLight Therapeutics, Inc. has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (1)
2024 (1)

Funding

Current Stage
Public Company
Total Funding
$640.6M
Key Investors
Michael J. Fox Foundation
2025-10-27IPO
2025-07-28Series D· $372.5M
2023-10-30Series C· $225M

Leadership Team

leader-logo
Vishwas Setia
Chief Financial Officer
linkedin
Company data provided by crunchbase